Flexion Therapeutics Inc(FLXN)stock report

Flexion Therapeutics, Inc. is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid. The Company is developing Zilretta as a treatment for patients with moderate to severe OA knee pain. The Company has specifically designed Zilretta to combine a steroid, triamcinolone acetonide (TCA) with poly lactic-co-glycolic acid (PLGA), for providing sustained therapeutic concentrations in the joint and persistent analgesic effect. The Company’s other product candidates include FX007 for post-operative pain and FX005 for the treatment of end-stage OA patients. The Company is engaged in conducting a Phase IIb clinical trial of Zilretta.

Finance:
Q3 2019(9/30/19): Cash 176M. Loss 37.97M

EPS and Sales:
https://finance.yahoo.com/quote/FLXN/financials?p=FLXN

Date EPS % last year % last quarter
2018.12.31 -4.471 -22.31% 31.01%
2019.3.31 -1.0933 1.02% 75.55%
2019.6.31 -2.0537 9.13% 13.29%
2019.9.30 -3.0508 10.60% -48.55%

 

Date Sales % last year % last quarter
2018.12.31 22.52M 6244.79% 42.36%
2019.3.31 10.56M 381.50% -53.11%
2019.6.31 27.52M 359.31% 160.61%
2019.9.30 49.3M 279.81% 79.14%

 

Insider Transactions:
http://insidercow.com/history/company.jsp?company=FLXN&B1=Search%21

Institution Ownership:
https://www.marketbeat.com/stocks/NYSE/FLXN/institutional-ownership/

2019.12.09:
Total institutions: 147,no change
Shares hold: 35074.3k shares. no change
shares% hold: 91.88%,no change

Analyst Ratings:
https://www.tipranks.com/stocks/FLXN/price-targe

Leave a Reply